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Prevention of genital herpes and other sexually transmitted infections (STI) is a critical health priority
because of the overwhelming impact on women and infants and the epidemiological association with human
immunodeficiency virus (HIV)/AIDS. Small animal models are essential for evaluating strategies for preven-
tion or treatment of STI. Neither the murine nor the guinea pig model of genital herpes fully recapitulates
human disease. We demonstrate that herpes simplex virus type 2 (HSV-2) readily infects inbred cotton rats
(Sigmodon hispidus). Consistent infection does not require pretreatment with medroxyprogesterone, and pri-
mary disease resembles that observed in humans. The animals develop genital lesions and fully recover. During
primary infection, viral DNA is also detected in liver, lungs, brain, and kidneys. Clinical self-limited recur-
rences occur spontaneously but may also be induced by dexamethasone. Pretreatment of cotton rats with PRO
2000 gel, a candidate vaginal microbicide being evaluated in clinical trials to prevent HSV and HIV, protects
cotton rats from HSV. Together, these studies suggest that the cotton rat may provide an excellent model to
study genital herpes and to evaluate preventive strategies.
Genital herpes is one of the most prevalent sexually trans-
mitted infections (STI) worldwide and is associated with sub-
stantial morbidity. Population-based studies in developing
countries show herpes simplex virus type 2 (HSV-2) seropreva-
lence rates ranging from 60 to 80% in young adults (15). What
makes HSV infections so difficult to control is that most sexual
and vertical transmission occurs during unrecognized or
asymptomatic shedding (15). Epidemiological studies consis-
tently demonstrate that genital herpes enhances the transmis-
sion of human immunodeficiency virus (HIV) (7). HSV may
facilitate HIV acquisition by disrupting epithelial cells, thereby
increasing exposure to HIV target cells, and may modulate the
mucosal environment by activating proinflammatory or sup-
pressing protective factors (14, 26). The increasing prevalence
of genital herpes, the frequent recurrence of clinical episodes,
the high frequency of asymptomatic shedding, and the associ-
ation of HSV with HIV transmission highlight the urgent need
for control measures in populations at risk for both viruses.
One preventive strategy is the development of topical mi-
crobicides, self-administered agents designed for vaginal use to
prevent STI. Goals for the development of topical microbicides
are that they be safe; affordable; effective against HIV, HSV,
and other STI; and stable in the presence of genital tract
secretions. A key component to the preclinical development of
topical microbicides is evaluation of safety and efficacy in small
animal models that reflect human disease. Most small animal
studies of the pathogenesis of and preventive therapies for
genital herpes have been conducted using murine models. Ad-
vantages include small size, inexpensiveness, the availability of
large numbers of inbred strains and gene knockout strains, and
a wide range of reagents available for study. However, the
mouse is not an optimal model of human disease. First, con-
sistent infection requires treatment with medroxyprogesterone
to induce a diestrous phase (25). Hormonal treatment may be
important for thinning of the vaginal mucosa but also may
influence innate and adaptive immune responses to the virus
(10, 11). Human infection and clinical or subclinical reactiva-
tions appear to occur independently of the menstrual cycle (4).
Second, genital herpes infection of mice spreads to the para-
cervical ganglia, which are the major autonomic ganglia of the
pelvis, resulting in urinary and rectal distention, hind-limb pa-
ralysis, and death, outcomes not observed in human disease
(24). The high rates of mortality preclude studies of horizontal
and vertical transmission and of the impact of preventive strat-
egies on the establishment of latency or frequency of clinical
and subclinical reactivations.
An alternative model that permits studies of recurrent dis-
ease is the guinea pig (31, 32). The guinea pig model more
closely resembles human disease but also has substantial lim-
itations. Disadvantages include the paucity of inbred strains
and limited availability of immunologic reagents. This is par-
ticularly relevant to studies designed to test the safety of can-
didate topical microbicides because a model that enables in-
vestigators to carefully evaluate the effects of repeated applications
of microbicides on the mucosal environment and innate im-
munity is critical.
The cotton rat, a common New World rodent, in a family
distinct from the common laboratory mouse and rat, is a well-
established model of several human viral diseases, most nota-
bly, respiratory syncytial virus, measles, and parinfluenza virus
type 3 (21–23, 27–29, 36–39). For reasons that remain unclear,
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the cotton rat is susceptible to human viruses where murine
models have failed. The importance of this animal as a model
of several clinically important human diseases has led to the
recent development of reagents that will permit study of mu-
cosal immunity in this animal model (1, 2). Recently, we found
that the cotton rat is an excellent model of HSV-1 infections of
the lip (herpes labialis) (16). Building on these observations,
we explored the potential role of cotton rats as a model of
genital herpes.
MATERIALS AND METHODS
Intravaginal inoculation of cotton rats. Inbred female Sigmodon hispidus cot-
ton rats (Virion Systems, Inc., Rockville, MD) were maintained and handled
under veterinary supervision in accordance with National Institutes of Health
guidelines and the Virion Institutional Animal Care Utilization Committee. For
inoculations, 6-week-old female cotton rats (80 g each) were anesthetized with
ketamine (10 mg/kg of body weight) and xylazine (6 mg/kg). The vaginal vault
was gently swabbed with a wet calcium alginate-tipped swab and then a dry
calcium alginate-tipped swab to remove mucus, and then groups of 20 rats were
inoculated with a sterile cotton swab containing 102, 103, or 104 PFU of HSV-
2(G) inserted into the vagina for 30 min. Six cotton rats were mock infected and
served as controls. The animals were observed daily for 3 weeks and twice weekly
for an additional 10 weeks. Alternatively, cotton rats were inoculated with 30 l
of virus suspension (103, 104, or 105 PFU per animal) using a pipette. In the first
experiment only, cotton rats were pretreated with a single intramuscular dose of
4-mg/kg medroxyprogesterone 24 h prior to infection.
Recovery of infectious virus and detection of virus by PCR. Vaginal swabs
were obtained with a premoistened cotton swab on days 1, 2, 3, 4, 5, 7, 10, 14, and
21 postinfection (p.i.). The applicators were placed directly into sterile micro-
tubes containing 0.5 ml minimal essential medium with antibiotics and Fungi-
zone (Cambrex, Walkersville, MD) and stored at 80°C. HSV titers were de-
termined by standard plaque assay of Vero cells grown in 96-well plates. In
addition, two animals per group were sacrificed on days 1, 3, 5, 7, 10, 14, 21, and
100, and the following tissues were isolated and flash frozen for PCR: lumbosa-
cral cord and dorsal root ganglia, brain, liver, lung, and kidney. Control animals
were sacrificed on day 100. DNA was isolated from dissected tissues using a
DNA isolation kit (DNeasy Tissue kit; QIAGEN, Valencia, CA), according to
the manufacturer’s specifications. The HSV thymidine kinase (TK) gene was
amplified by nested PCR using Taq DNA polymerase (Platinum Taq DNA
polymerase; Invitrogen, Carlsbad, CA). In the first PCR round, DNA samples
FIG. 1. HSV induces genital tract lesions as early as 4 days p.i., independent of inoculum dose or treatment with medroxyprogesterone
(MP). Results are the number of cotton rats in each group (five rats per group) with clinically evident genital tract lesions at the indicated
time p.i.
FIG. 2. The average size of the lesions (in millimeters) per infected cotton rat during primary HSV infection peaks on day 14 p.i. and increases
with inoculum dose. Results are geometric means of the sizes of the lesions from six infected animals per group per time.
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(200-ng aliquots) were incubated with HSV TK-specific primers (5-AATCGC
GAACATCTACACCAC-3 and 5-AAAGCTGTCCCCTTACCTCCC-3) and
subjected to 30 PCR cycles (each cycle consisting of 94°C for 45 s, 58°C for 45 s,
and 72°C for 1 min, except in the last cycle, which was 72°C for 12 min). For the
second round of PCR, 3 l of the first-round reactions was incubated with the
primers 5 CTGCAGATACCGCTCCGTATT-3 and 5-CATCTTCGACCG
CCATCCCAT-3 and subjected to 30 PCR cycles under the same conditions as
the first cycle. For reaction controls, the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was amplified using nested PCR as pre-
viously described (16). The amplified products were analyzed by agarose gel
electrophoresis. The HSV TK-amplified gene product was 266 bp, and
GAPDH was 230 bp.
PRO 2000 protection study. Female cotton rats were pretreated with 4% PRO
2000 gel, a matched placebo gel, or phosphate-buffered saline (PBS) (15 animals
per group). Indevus Pharmceuticals, Lexington, MA, provided the gels (18, 34).
Animals were anesthetized, and a moistened cotton swab was used to clean the
mucosal lining. A 1.0-ml syringe was used to load the gel and a 0.15-ml volume
was inserted into the vaginal vault. Fifteen minutes later, 10 rats in each group
were intravaginally inoculated with 0.1 ml HSV-2(G) at 105 PFU/ml; the other
5 rats were mock infected with PBS as controls. The animals were swabbed daily
for 30 days and twice a week for additional 30 days. On days 3, 7, and 14, two
animals from each infected groups were sacrificed and brain, liver, lung, kidney,
and vaginal tissues were removed for PCR and histology.
RESULTS
Cotton rats are susceptible to genital HSV infection inde-
pendent of progesterone therapy. To determine if female cot-
ton rats are susceptible to intravaginal infection and whether
infection requires pretreatment with medroxyprogesterone,
6-week-old female cotton rats were treated with 4-mg/kg me-
droxyprogesterone or sham injected and were infected intra-
vaginally 24 h later with a cotton swab containing 102, 103, or
104 PFU of HSV-2(G) for 30 min. Animals were observed daily
for 3 weeks and twice weekly for an additional 10 weeks.
Almost all of the animals (29/30) developed lesions by day 12,
independent of whether they received medroxyprogesterone
24 h prior to infection (Fig. 1). Epithelial lesions developed at
the vaginal opening beginning 4 days after infection and in-
creased in size to a maximum at day 14 (Fig. 2). The histolog-
ical appearance of the lesions was characterized by ballooning
degeneration of squamous epithelium, polymorphonuclear in-
filtration of damaged epithelium, and florid polymorphonu-
clear vaginitis, similar to the appearance of HSV-2 lesions in
humans (data not shown). The size and number of the primary
lesions increased (data not shown) with larger amounts of
inoculum, while the duration of lesions did not vary (Fig. 2).
Additionally, the extent of inflammation surrounding the vag-
inal wall appeared to increase with larger amounts of inoculum
(data not shown). None of the animals developed significant
neurological findings (e.g., hind-limb paralysis) requiring sac-
rifice, and no animals died during the 21 days of initial obser-
vation.
Cotton rats undergo spontaneous and induced clinical re-
activation of genital herpes. The genital tract lesions resolved
in all of the female rats by day 26 and subsequently 60 to 70%
of the animals, independent of initial inoculum dose, devel-
oped spontaneous clinical recurrences with lesion formation.
The lesions associated with reactivation tended to be smaller
than those observed during primary infection (Fig. 3). The
time course of spontaneous reactivation is illustrated for 15
rats with spontaneous recurrences (Fig. 4). To determine if
reactivations could also be experimentally induced, 19 animals
received a single intramuscular dose of dexamethasone (4 mg/kg)
on day 105 postinfection and were observed for an additional
21 days. Recurrent lesions were seen at a rate that was two- to
threefold higher than the rate of spontaneous reactivation
(Fig. 5).
Primary HSV infection is associated with dissemination to
extragenital tissues. Rather than inserting a cotton swab into
the vagina for 30 min, we also examined the susceptibility
to HSV infection if cotton rats were inoculated intravaginally
with 30 l of virus suspension with a pipette, as this is the
protocol typically used in murine studies. No animals were
pretreated with medroxyprogesterone. The animals were ob-
served for 2 months to document the incidence of primary and
recurrent lesions. Using this mode of viral inoculation, the
dose required to achieve comparable rates of primary clinically
apparent infection was higher, with 90% of animals receiving
105 PFU, 40% receiving 104 PFU, and 70% receiving 103 PFU
developing primary lesions (Fig. 6). Spontaneous recurrences
of lesions were also observed independent of whether the ini-
tial inoculum was delivered using a pipette or a cotton swab.
In humans, primary genital herpes infections may be asso-
ciated with constitutional symptoms, aseptic meningitis, and
clinically asymptomatic spread of the virus to liver, lungs, and
kidneys. To determine whether primary HSV-2 infection is
associated with evidence of viral spread in the cotton rat,
several animals from each group were sacrificed at different
days postexposure, and organs were harvested for histopathol-
ogy and for viral detection by PCR. Figure 7A depicts results
obtained from one animal 3 days post-vaginal inoculation with
105 PFU of virus. Viral DNA was detected in vaginal swab,
kidney, brain, lumbosacral cord (including dorsal root ganglia),
FIG. 3. Representative photographs illustrating primary and spon-
taneous or dexamethasone-induced recurrent genital tract lesions.
(A) Cotton rat inoculated with 105 PFU HSV-2, shown 1 day postin-
fection (left) and the same cotton rat 35 days p.i.; arrows indicate a
spontaneous recurrent ulcer. (B) Representative photographs of cot-
ton rats during primary and dexamethasone-induced recurrences. Top
left, mock infected, 7 days p.i.; top middle, 104 PFU of HSV-2, 7 days
p.i; top right, 104 PFU of HSV-2, 14 days p.i.; bottom left, recurrence
12 days post-dexamethasone treatment; bottom middle, recurrence
18 days post-dexamethasone treatment; bottom right, recurrence 21
days post-dexamethasone treatment.
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and liver but not in sciatic nerve or lung. Table 1 shows cumu-
lative results obtained from several animals representing each
group at different times p.i. Viral DNA was readily detected in
vaginal swabs on days 3, 5, and 7 p.i. and could also be detected
in the liver, lung, kidney, lumbosacral cord, and brain on the
same days; viral DNA was only detected in the lung on day 3
but not at the later times. Additionally, within the same exper-
iment, brain and lumbosacral cord were examined 100 days
postinfection in one animal; viral DNA was detected in lum-
bosacral cord but not the brain, suggesting a state of latency in
cotton rat dorsal root ganglia (Fig. 7B). The presence of com-
parable amounts of DNA was confirmed by GAPDH amplifi-
cation (data not shown).
Different assays are used both in clinical studies and in
animal models to detect the presence of HSV in the genital
tract and include the presence of clinical lesions, detection of
infectious virus by culture, or presence of viral DNA by PCR.
To examine the time course of viral detection by PCR, culture,
and the presence of clinical symptoms, we followed one cotton
rat clinically and obtained daily vaginal swabs. Results indi-
cated that virus was detected in the vagina by either PCR or
culture of vaginal swabs prior to the onset of clinical lesions
(Fig. 8). In addition, intermittent spontaneous viral shedding
was observed in the absence of clinical lesions. Moreover, virus
was also detected by PCR and culture prior to the onset of a
clinical recurrence; these findings are consistent with those
observed with human HSV infection.
Efficacy of topical microbicides against HSV-2 infection in
the cotton rat model. Several candidate microbicides are cur-
rently in large phase IIb/III clinical trials. Two of these trials
FIG. 4. Time course of spontaneous clinical recurrences of genital lesions in each cotton rat.
FIG. 5. HSV recurrences can be induced following dexamethasone (Dex) treatment. The percentage of cotton rats that developed clinical
recurrences following treatment intramuscularly with dexamethasone (4 mg/kg) administered 105 days p.i.
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involve the candidate drug PRO 2000, a synthetic naphthalene
sulfonic acid polymer, that interacts with viral glycoproteins
HIV gp120 and HSV-2 glycoprotein B to prevent viral entry
and infection (6). PRO 2000 gel has been shown to inhibit
vaginal simian/human immunodeficiency virus infection in ma-
caques (36), HSV-2 infection in mice (3), and gonorrhea in
mice (30). To examine its effect in the cotton rat, cotton rats
were pretreated with PRO 2000 (4% gel), a matched placebo
gel, or PBS; 15 min later, the rats were challenged by intra-
vaginal inoculation with 104 PFU of HSV-2 G (100-l suspen-
sion). All of the cotton rats that received PRO 2000 gel
(10 rats) were protected from infection and disease, as shown
by the absence of any detectable virus by determining titers by
plaque assay or detecting DNA by PCR of vaginal swabs and
the absence of clinical signs of disease (Table 2). In contrast,
8/10 rats that received vehicle and 9/10 rats that received PBS
developed primary lesions (Table 2). The animals were ob-
served daily for 14 days and three times a week for additional
46 days. Representative PCR results obtained from three an-
imals from each group (PRO 2000, vehicle, and PBS) demon-
strate that no virus was detected from the PRO 2000 group by
nested PCR, whereas virus was readily detected from vaginal
swabs in the vehicle- or PBS-treated group (Fig. 9).
DISCUSSION
These studies indicate that the cotton rat provides a poten-
tially biologically superior model of human genital disease
relative to the mouse or guinea pig and may prove an excellent
model to test candidate microbicides for efficacy and safety.
The salient features of this model are that vaginal infection
does not require hormonal manipulation, primary infection is
associated with spread of virus to other organs known to be
targets of HSV dissemination in humans such as the liver,
animals recover from primary infection but are prone to spon-
taneous clinical recurrences that mimic human disease, and
infection is prevented by pretreatment with a candidate topical
microbicide. Additional advantages include the availability of
reagents to study the mucosal response to HSV and to micro-
bicides, the ability to induce reactivation experimentally with
dexamethasone, the potential to study vertical and horizontal
transmission, and the possibility of developing the cotton rat as
a model of coinfection with other STI.
Primary infection in cotton rats closely mimicked that ob-
FIG. 6. Primary genital herpes following intravaginal application of virus introduced by pipette. Percentages of cotton rats developing clinical
lesions at the indicated times (in days) following intravaginal inoculation with HSV-2(G) introduced by pipette (eight rats per group) are shown.
FIG. 7. Tissues were extracted and examined by PCR for HSV
DNA. (A) Results from one representative animal that was sacrificed
3 days p.i. (105 PFU). Lane 1, DNA ladder; lane 2, vagina; lane 3,
kidney; lane 4, brain; lane 5, sciatic nerve; lane 6, lumbosacral cord;
lane 7, liver; and lane 8, lung. (B) Brain and lumbosacral cord (includ-
ing dorsal root ganglia) were extracted from an animal 100 days p.i.
with 105 PFU HSV-2. Lane 1, DNA ladder; lane 2, negative control;
lane 3, HSV DNA (positive control); lane 4, HSV DNA (positive
control); lane 5, brain; lane 6, lumbosacral cord.
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served in humans. The pattern of dissemination is similar to
that observed in human disease, in which extragenital compli-
cations of primary HSV-2 infection include aseptic meningitis
and dissemination to liver, lung, and kidney. Dissemination to
these other sites is usually clinically silent but may cause dis-
ease in immunocompromised hosts, such as neonates, trans-
plantation recipients, and persons with AIDS.
Although both mouse and guinea pig models have yielded
important information, neither of these models fully recapitu-
lates human disease. This is particularly problematic with the
mouse, where the model is only consistently permissive for
HSV following treatment with medroxyprogesterone. It had
been presumed that the major impact of hormonal treatment is
to induce thinning of the vaginal epithelium, rendering the
mouse more susceptible to pathogens. However, this notion
has been recently challenged. Kaushic and colleagues demon-
strated that medroxyprogesterone treatment of mice resulted
in a 100-fold increase in susceptibility to genital HSV-2 com-
pared to untreated mice at diestrous phase (12). Furthermore,
long-term effects of medroxyprogesterone treatment included
reduction in protective immunity to HSV-2. Moreover, the
expression of nectin-1, a key coreceptor for HSV entry, is
expressed on the superficial epithelial cells of the mouse vagina
only during the susceptible diestrous and proestrous phases of
the estrous cycle. In contrast, human vaginal epithelium ex-
presses nectin-1 at all stages of the menstrual cycle (17). These
findings again highlight differences between a mouse model
and human disease.
The morbidity and mortality associated with HSV infection
in the murine model preclude its use to study horizontal or
vertical transmission or to evaluate strategies designed to pre-
vent reactivation. Preventing reactivation has been increasingly
recognized as an important public health priority. Epidemio-
logical studies consistently demonstrate that recurrent HSV
increases the risk of HIV acquisition, enhances HIV replica-
tion, and itself can be associated with serious morbidity and
mortality, especially among neonates and immunocompro-
mised hosts (5, 20). Longitudinal studies indicate that clinical
and subclinical viral reactivation occurs relatively frequently
and is associated with sexual transmission of HSV, even be-
tween monogamous individuals. Although prophylactic antivi-
ral therapy reduces the frequency and degree of viral shedding
and lowers the transmission rate in discordant monogamous
couples, transmission still occurs (8). With respect to HIV, a
study conducted among a cohort of monogamous HIV-1 dis-
cordant couples from Rakai, Uganda, demonstrated that the
per-contact risk of HIV acquisition, which averaged 0.0011,
was fivefold higher if the susceptible partner was HSV-2 sero-
positive rather than seronegative (9). Although the probability
of HIV acquisition was highest if the susceptible partner had
genital ulcer disease, the risk was also increased with asymp-
tomatic HSV, suggesting that subclinical reactivation is almost
as important as clinical disease in increasing the risk of HIV
acquisition. In contrast, symptoms of urethritis and laboratory-
confirmed diagnoses of gonorrhea, Chlamydia infection, and
trichomoniasis did not increase HIV risk. Additionally, several
studies have shown that subclinical HSV reactivation is asso-
ciated with increased replication of HIV. The quantity of HSV
DNA correlates with HIV-1 RNA in cervicovaginal secretions
of women without genital lesions (19, 20). Taken together,
these epidemiologic studies support the hypothesis that control
of HSV-2 reactivation may help reduce HIV transmission.
The cotton rat provides an animal model to test strategies
designed to reduce reactivation. Specifically, we found that
spontaneous clinical recurrences occur as frequently as every
9 days, are self limited with smaller lesion size, and are often
preceded by virus being detected in vaginal swabs by PCR or
culture. Virus was not always detected at the time that genital
lesions appeared. Similar results were reported in a study cor-
relating symptoms of recurrences and viral shedding (35).
Moreover, reactivation is induced in 50% of cotton rats fol-
FIG. 8. Representation of one cotton rat infected with 104 PFU of HSV-2(G), monitored for HSV by PCR culture of vaginal washes and by
clinical symptoms.
TABLE 1. Number of animals in which HSV was detected by PCR
of tissue harvested 3, 5, or 7 days following viral infection
with the indicated viral inoculuma
Tissue
Viral inoculum at indicated day p.i.
105 PFU 104 PFU 103 PFU Total
No. of days p.i. 3 5 7 3 5 7 3 5 7 3 5 7
Vagina 7/7 1/1 1/2 5/5 ND 1/1 ND 1/1 2/2 12/12 2/2 4/5
Liver 2/2 2/2 1/1 1/2 2/2 2/2 2/2 2/3 1/1 5/6 6/7 4/4
Lung 2/2 0/2 0/2 1/2 0/2 0/1 1/2 0/2 0/1 4/6 0/6 0/4
Kidney 1/2 0/2 1/2 ND 2/2 2/2 1/2 1/1 1/2 2/4 3/5 4/6
LS cord 2/2 0/2 1/1 2/2 0/2 0/1 1/2 0/2 0/1 5/6 0/6 1/3
Brain 2/2 1/2 1/2 ND 1/2 ND 0/2 0/1 1/1 2/4 2/5 2/3
a ND, not done; LS, lumbosacral. Values for vagina, liver, and other tissues are
the number of samples testing positive for HSV/total number of samples tested.
TABLE 2. PRO 2000 protects cotton rats from infection
and diseasea





PBS 10/10 10/10 9/10
Vehicle 10/10 10/10 8/10
4% PRO 2000 0/10 0/10 0/10
a Values indicate number of rats testing positive/total number tested.
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lowing dexamethasone therapy, which may provide a model for
reactivation in the setting of immune suppression. Although
spontaneous recurrences also occur in guinea pigs, the number
of reagents available for studying mucosal immunity in guinea
pigs is limited. In contrast, there has been recent expansion
and development of a library of cotton rat genes that have been
sequenced, including genes expressing cytokines, chemokines,
cell surface markers, transcriptional factors, and membrane-
associated proteins. This has fostered the development of a
wide array of reagents, which include primers and probes,
recombinant proteins, polyclonal and monoclonal antibodies,
and enzyme-linked immunosorbent assays for cytokines, che-
mokines, and other important cell surface molecules and pro-
teins. Recognition that repeated microbicide exposure may
alter the genital tract environment, leading to increased sus-
ceptibility to HIV, as was observed for nonoxynol-9 (33), has
prompted investigators to prioritize a rigorous evaluation of
the mucosal responses to candidate microbicides as a priority
in their preclinical evaluations (13). However, animal models
that provide surrogate markers of safety that correlate with
clinical outcomes have not been identified. These studies sug-
gest that the cotton rat may provide an appropriate model for
evaluation of the safety and effectiveness of candidate micro-
bicides and other preventive strategies.
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